Results 121 to 130 of about 1,208,573 (299)

[Efficacy of metformin in abdominal obesity].

open access: yesTerapevticheskii arkhiv, 2014
To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO).The results of using metformin 2000 mg daily for 3 months in 46 patients with AO. The comparison group consisted of 50 people.
A M Mkrtumian   +4 more
openaire   +2 more sources

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor   +11 more
wiley   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu   +13 more
wiley   +1 more source

Adipose tissue NAD+-homeostasis, sirtuins and poly(ADP-ribose) polymerases -important players in mitochondrial metabolism and metabolic health

open access: yesRedox Biology, 2017
Obesity, a chronic state of energy overload, is characterized by adipose tissue dysfunction that is considered to be the major driver for obesity associated metabolic complications.
Riikka Jokinen   +3 more
doaj   +1 more source

Misuse of obesity drugs exposes patients to serious and preventable harms: A French nationwide pharmacovigilance case series

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction The rapid uptake of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for obesity has been accompanied by increasing use outside approved indications and medical supervision. Evidence regarding the harms associated with such misuse remains limited because these situations are not captured in clinical trials and are difficult to ...
Jean‐Luc Faillie
wiley   +1 more source

Criteria for EASO-Collaborating Centres for Obesity Management

open access: yes, 2011
Obesity is recognised as a global epidemic and the most prevalent metabolic disease world-wide. Specialised obesity services, however, are not widely available in Europe, and obesity care can vary enormously across European regions.
Hermann Toplak   +35 more
core   +1 more source

An Obesity Dietary Quality Index Predicts Abdominal Obesity in Women: Potential Opportunity for New Prevention and Treatment Paradigms

open access: yesJournal of Obesity, 2010
Background. Links between dietary quality and abdominal obesity are poorly understood. Objective. To examine the association between an obesity-specific dietary quality index and abdominal obesity risk in women. Methods.
Dolores M. Wolongevicz   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy